OraSure Technologies OSUR Income (Loss) from Continuing Operations before Equity Method Investments, Net of Tax
Income (Loss) from Continuing Operations before Equity Method Investments, Net of Tax at other companies
Other financials
Where this comes from
Reported directly by OraSure Technologies in its filing.
Tagged under the XBRL concept osur:IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax.
The official record: OraSure Technologies’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about OraSure Technologies's income (loss) from continuing operations before equity method investments, net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OraSure Technologies's income (loss) from continuing operations before equity method investments, net of tax?
- OraSure Technologies (OSUR) reported income (loss) from continuing operations before equity method investments, net of tax of -$21.29M in Q1 2026.
- How has OraSure Technologies's income (loss) from continuing operations before equity method investments, net of tax changed year-over-year?
- OraSure Technologies's income (loss) from continuing operations before equity method investments, net of tax decreased by 37.2% year-over-year, from -$15.52M to -$21.29M.
- What is the long-term trend for OraSure Technologies's income (loss) from continuing operations before equity method investments, net of tax?
- Over 2 years (2023 to 2025), OraSure Technologies's income (loss) from continuing operations before equity method investments, net of tax has grown at a 11.2% compound annual growth rate (CAGR), from $53.66M to -$66.39M.
- What does income (loss) from continuing operations before equity method investments, net of tax mean?
- This metric measures the profitability of the company's ongoing business operations after accounting for taxes but before considering the impact of equity method investments. It provides a focused view of the operational health and tax efficiency of the core business segments. By excluding equity-based earnings, it allows for a cleaner assessment of the company's primary diagnostic and molecular solutions performance.